Partial dopamine agonists in schizophrenia

Hospital Medicine

Volumn 66, Issue 5, 2005, Pages 300-303

  Launer, Mike ^a  

^a The Spinney   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CINNARIZINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; METOCLOPRAMIDE; OLANZAPINE; RISPERIDONE; ZOPICLONE;

AKATHISIA; ANXIETY DISORDER; BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DYSPHORIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; NAUSEA; NAUSEA AND VOMITING; NEGATIVE SYNDROME; POSITIVE SYNDROME; QT PROLONGATION; RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 20144364610     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2005.66.5.18426     Document Type: Review

References (9)

1. Casey DE, Carson WH, Saha AR et al (2003) Psychopharmacology (Berl.) 166: 391-9
2. Kasper S, Lerman MN, McQuade R et al (2003) Efficacy and safety of aripiprazole versus haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6: 325-37
3. Marder SR, McQuade RD, Stock E et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61: 123-36
4. McQuade RD, Jody DN, Kujawa MJ et al (2003) Long-term weight effects of aripiprazole vs olanzapine. Poster at American Psychiatric Association Annual Meeting. 17-22 May 2003. San Francisco, California
5. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2 suppl): 106S-15S
6. National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology appraisal guidance, No. 43. NICE, London
7. Otsuka Pharmaceuticals (2005) Abilify. Summary of product characteristics. Otsuka Pharmaceuticals (UK) Ltd, London
8. Pigott TA, Carson W, Saha A, Torbeyns AF, Stock EG, Ingenito GG (2003) Aripiprazole for the prevention of relapse in stabilised patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 64: 1048-56
9. Stahl SM (2002) Essential Psychopharmacology of Antipsychotics and Mood Stabilisers. 1st edn. Cambridge University Press, Cambridge